Sagimet Biosciences(US:SGMT)2025-11-13 12:36Financial Performance - Cash, cash equivalents, and marketable securities as of September 30, 2025, were $125.5 million[6] - Research and development expenses for the three and nine months ended September 30, 2025, were $9.7 million and $32.3 million, respectively, compared to $12.7 million and $24.2 million for the same periods in 2024[6] - General and administrative expenses for the three and nine months ended September 30, 2025, were $4.6 million and $13.8 million, respectively, compared to $4.2 million and $12.0 million for the same periods in 2024[6] - Net loss for the three and nine months ended September 30, 2025, was $12.9 million and $41.5 million, respectively, compared to $14.6 million and $29.4 million for the same periods in 2024[7] - Total operating expenses for the three and nine months ended September 30, 2025, were $14.3 million and $46.1 million, respectively[14] Clinical Trials and Drug Development - The Phase 1 clinical trial of denifanstat and resmetirom is ongoing, with topline data expected in the first half of 2026[3] - Sagimet plans to submit a New Drug Application (NDA) for denifanstat in China for the treatment of moderate-to-severe acne vulgaris[6] - The company has initiated a Phase 1 clinical trial of its second FASN inhibitor, TVB-3567, for acne indication[2] - Sagimet anticipates starting a Phase 2 clinical trial in moderate to severe acne patients in 2026, subject to regulatory consultation[6] - The company has a total of approximately 40 healthy adult participants enrolled in the Phase 1 PK trial of denifanstat and resmetirom[3]